Metrics as of 10/15/2026, 03:03 PM (Berlin time), refresh in progress.
Genmab A/S Stock
Genmab A/S
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- CEO
- Jan van de Winkel
- Employees
- 3,119
- Market cap
- $22.7 B
- IPO
- 01/06/2009
Genmab A/S is a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark. Operating within the healthcare sector, the company specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The commercialized…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Genmab A/S stock: price history
1D
+0.9%
1W
+0.7%
1M
+13.0%
6M
+25.9%
YTD
+19.8%
1Y
+12.6%
2Y
+55.9%
5Y
-17.0%
10Y
+122.0%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~9% weaker price swings than usual
Genmab A/S stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Genmab A/S is a biopharmaceutical company headquartered in Copenhagen that specializes in the discovery and development of innovative antibody therapies. The focus lies on treating cancer as well as other severe diseases such as multiple myeloma and chronic lymphocytic leukemia. The business model encompasses the distribution of already approved medicines as well as an extensive pipeline of new active substances in various clinical development phases. Through strategic collaborations and licensing agreements with partners from the pharmaceutical industry, the company further advances the research and development of its therapies.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Genmab A/S
Analyst assessment of Genmab A/S
PRICE TARGET LOW
US$38.00
CONSENSUS
US$44.75
MEDIAN
US$41.50
PRICE TARGET HIGH
US$58.00
0
STRONG BUY
13
BUY
4
HOLD
1
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 07/10/2026
Genmab A/S stock metrics
P/E
28.95
P/B
3.82
EV/EBITDA
19.05
RETURN ON EQUITY
5.1%
NET MARGIN
26.2%
DEBT/EQUITY
0.89
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.5%
FLOAT SHARES
587,079,370
AVG. DAILY VOLUME (30D)
3,278,970
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Genmab A/S stock
What does Genmab A/S do?
Genmab A/S is a company in the Healthcare sector, Biotechnology industry, headquartered in Denmark.
The CEO is Jan van de Winkel, the company employs around 3,119 people.
The IPO was on 01/06/2009; the stock trades on NASDAQ under the ticker GMAB.
What do analysts say about Genmab A/S stock?
18 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$44.75, ranging from US$38.00 to US$58.00, with a median of US$41.50.
This is an external assessment, not a statement by Market Jury.
When does Genmab A/S report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -9% stronger than usual.
Does Genmab A/S pay a dividend?
No, Genmab A/S currently does not pay a dividend.
Which stocks are comparable to Genmab A/S?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Exelixis.
How can I get Genmab A/S stock analyzed?
Clicking "Analyze stock" lets five strategies assess Genmab A/S against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.